Longevity. Is it a market and an investment category?

Yes, it’s emerging and it’s moving fast.

The advent of new and accelerating technologies such as Senolytics, Stem-Cells, AI, CRISPR, Bioprinting and Gene-therapy are already combining. Longevity is coming, and so are the investment risks and rewards.

What is Longevity?

Healthcare has already migrated from ‘cure’ to ‘intervention’ and will ultimately move to ‘prevention’. These new states: intervention and prevention, succinctly describe Longevity.

Isn’t Longevity simply better healthcare?

No. Where Longevity differs from wider healthcare developments is the sector’s focus on overcoming the hallmarks of aging to ultimately delay death; rather than the individual treatment of a specific disease.

Isn’t biotech, ultimately, the only viable solution for Longevity?

The road to ultra-Longevity will be long and so will the development and regulatory approvals for biotech R&D pipelines.

Meanwhile, early stage companies all around the world are releasing nanobots, reprogramming nerve signals and applying AI to create highly complex contributions life extension. This is why we address these areas with as much vigour and interest.

The Longevity Market Map

In the absence of consensus a position is required: we have created version 1.0 of the technologies that make-up the emerging Longevity market:

Longevity: the new investment category

Remember when every company that was in financial software suddenly became a fintech company? Fast-forward a few years from now and it will be the same with Longevity.

Age-tech, still (ironically) in its youth as an industry, has already become a $700bn per annum market (we cover this as a domain) but Longevity is wider and the opportunities are deeper.

We would be delighted if you were to join us on our journey. You can sign-up today for daily news, for free.